Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

Share this content:
A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.
A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.
The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.

First-line atezolizumab maintained durable clinical activity in patients with non–small cell lung cancer (NSCLC) regardless of EGFR or KRAS mutational status after more than 2 years of follow-up, according to an oral abstract presentation at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Yokohama, Japan.1

A previous analysis of the phase 2 BIRCH study (ClinicalTrials.gov Identifier: NCT02031458) showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy. Researchers identified the level of PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC), and enrolled patients who were TC2/3 or IC2/3 (5% or greater expression of PD-L1). Eligible patients were chemotherapy-naïve and had advanced local or metastatic NSCLC. Patients with an EGFR mutation or ALK rearrangement had received prior TKI therapy.

At the median follow-up of 29.7 months, patients who were TC3 or IC3 had an overall survival (OS) of 26.9 months. The OS in all treated patients was 24.0 months.

Patients who were in the TC3/IC3 also had an objective response rate (ORR) of 35%; the ORR in all treated patients was 26%. The ORR was 31% and 23% for patients with mutant EGFR vs patients with wild-type EGFR, respectively, and was 31% and 24% for patients with mutant KRAS vs wild-type KRAS.

The authors concluded that “atezolizumab monotherapy has promising activity as a frontline therapy. Ongoing phase III trials are evaluating atezolizumab-based regimens vs chemotherapy in 1L NSCLC.”

Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Carcereny E, Felip E, Reck M, et al. Updated efficacy results from the BIRCH study: first-line atezolizumab therapy in PD-L1-selected patients with advanced NSCLC. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; Yokohama, Japan: October 15-18, 2017. Abstract OA 17.02.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs